Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
HOME > BUSINESS
BUSINESS
- EMA Accepts Application for Once-Weekly Oral Proteasome Inhibitor Ixazomib: Takeda
August 24, 2015
- Lilly Challenges Invalidation Ruling on Evista Usage Patent
August 21, 2015
- Astellas to Adopt One-Rep-for-One-Institution Regime in October
August 21, 2015
- Loxonin Suffers Most in Decrease in No. of Prescriptions Following Introduction of Generic Coefficient: Survey
August 21, 2015
- Announcement: 2015 Asia Pacific Meetings of ISMPP (Beijing on Aug. 30, Tokyo on Sept. 2)
August 20, 2015
- Anti-PD-L1 Antibody Atezolizumab Demonstrates Tumor Reduction Efficacy in NSCLC in PII Study: Roche
August 20, 2015
- Rheumatism Specialty Firm Ayumi Eyes Sales of 40-60 Billion Yen in 10 Years
August 19, 2015
- Shionogi Files Patent Suit over MSD’s HIV Drug
August 19, 2015
- Sawai’s Evista Generic Approved after Patent Battle
August 18, 2015
- Gene Techno Science, Mochida Tie Up for Joint Development of Biosimilars
August 18, 2015
- NBI Files for Micardis, Amlodipine, Diuretic Triple Combination Agents
August 18, 2015
- ASCO Immunotherapy Roundup - 7: Patient Group Hails Dawn of New Cancer Treatment Era
August 14, 2015
- Otsuka’s US Subsidiary Wins Patent Lawsuit over PBA Treatment
August 14, 2015
- Japan’s Diabetes Market to Exceed 600 Billion Yen in 2023: Fuji Keizai
August 14, 2015
- Kyowa Kirin Looks to Derive 40% of Sales Overseas by 2020, Split from Holdings Firm Won’t Happen: Pres.
August 13, 2015
- Hospira Japan’s Generic Oxaliplatin Approved for Gastric Cancer
August 13, 2015
- Ethical Drug Sales Up 9.8% in June: Crecon Report
August 13, 2015
- INCJ Invests 600 Million Yen in Drug Discovery Venture Founded by Tokyo Medical and Dental Univ.
August 12, 2015
- ASCO Immunotherapy Roundup - 6: CAR T-Cell Therapy Another Hot Field in Immuno-Oncology
August 12, 2015
- Quintiles to Set Up Unit for Medical Devices and Regenerative Medicines
August 12, 2015
ページ
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…